Table 3 SE, SP, PPV and NPV for TDM methods for detecting virologic failure for different ARV drugs
Drug | SE (95% CI) | SP (95% CI) | PPV (95% CI) | NPV (95% CI) |
|---|---|---|---|---|
Nevirapine | 27.7 (16.8–38.6) | 94.0 (89.6–98.3) | 72.0 (54.4–89.6) | 69.9 (62.7–77.1) |
Efavirenz | 41.6 (30.6–52.6) | 89.1 (85.0–93.2) | 57.1 (44.2–70.1) | 81.4 (76.5–86.3) |
Lopinavir | 44.1 (27.4–60.8) | 83.3 (68.4–98.2) | 78.9 (60.6–97.3) | 51.3 (35.6–67.0) |
Atazanavir | 53.3 (28.1–78.6) | 85.7 (70.7–99.0) | 72.7 (46.4–99.0) | 72.0 (54.4–89.6) |
Overall | 38.2 (31.3–45.1) | 90.1 (87.1–93.1) | 65.8 (56.9–74.6) | 74.5 (70.5–78.4) |